Michael Wang, Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center, shared by UT MD Anderson, adding:
“CAR T cell therapy in mantle cell lymphoma are usually done after BTK inhibition failure. Today FDA approved the usage of brexucabtagene autoleucel in patients who never received BTK inhibition. It is a great step forward!”
Quoting UT MD Anderson‘s post:
“The FDA has approved breuxcabtagene autoleucel for treating patients with relapsed or refractory mantle cell lymphoma, following a trial led by our Dr. Michael Wang.
Other articles featuring Michael Wang.